 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ASP2390 / Astellas
Trial primary completion date: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (clinicaltrials.gov) - Aug 17, 2022
P1, N=28, Active, not recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial primary completion date: Dec 2026 --> Dec 2022
- | ASP2390 / Astellas
Trial completion date, Trial primary completion date: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (clinicaltrials.gov) - Jan 19, 2022
P1, N=28, Active, not recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial primary completion date: Dec 2026 --> Dec 2022 Trial completion date: Feb 2023 --> Dec 2026 | Trial primary completion date: Feb 2023 --> Dec 2026
- || ASP2390 / Astellas
Enrollment closed: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (clinicaltrials.gov) - Oct 29, 2021
P1, N=28, Active, not recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial completion date: Feb 2023 --> Dec 2026 | Trial primary completion date: Feb 2023 --> Dec 2026 Recruiting --> Active, not recruiting
- | ASP2390 / Astellas
Trial completion date, Trial primary completion date: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (clinicaltrials.gov) - Aug 30, 2021
P1, N=28, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Recruiting --> Active, not recruiting Trial completion date: Aug 2026 --> Feb 2023 | Trial primary completion date: Aug 2026 --> Feb 2023
- | ASP2390 / Astellas
Trial completion date, Trial primary completion date: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (clinicaltrials.gov) - Feb 23, 2021
P1, N=28, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial completion date: Aug 2026 --> Feb 2023 | Trial primary completion date: Aug 2026 --> Feb 2023 Trial completion date: Apr 2026 --> Aug 2026 | Trial primary completion date: Apr 2026 --> Aug 2026
- || ASP2390 / Astellas
Trial initiation date: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (clinicaltrials.gov) - Nov 6, 2020
P1, N=28, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial completion date: Apr 2026 --> Aug 2026 | Trial primary completion date: Apr 2026 --> Aug 2026 Initiation date: Feb 2020 --> Oct 2020
- || ASP2390 / Astellas
Enrollment open: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (clinicaltrials.gov) - Sep 16, 2020
P1, N=28, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Initiation date: Feb 2020 --> Oct 2020 Suspended --> Recruiting
- ||| ASP2390 / Astellas
Trial suspension: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (clinicaltrials.gov) - May 15, 2020
P1, N=28, Suspended, Sponsor: Astellas Pharma Global Development, Inc.
Suspended --> Recruiting Recruiting --> Suspended
- || ASP2390 / Astellas
Enrollment open: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (clinicaltrials.gov) - Mar 26, 2020
P1, N=28, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Recruiting --> Suspended Not yet recruiting --> Recruiting
- || ASP2390 / Astellas
New P1 trial: A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites (clinicaltrials.gov) - Dec 3, 2019
P1, N=28, Not yet recruiting, Sponsor: Astellas Pharma Global Development, Inc.